KannaLife Sciences Inc. will continue to breathe new life to pharmacological products this year through research and development, as they had recently received Series A financing amounting to $1.5 million.
The company’s Founder and Chief Executive Officer Dean Petkanas shares more about this recent achievement in this e-interview with Lead411:
Mirna Therapeutics, Inc. will be looking into further research and product development with the help of their most recent equity funding round worth $1.5 million.
They have also enjoyed a couple of successful financing rounds from the Texas Emerging Technology Fund back in 2009 (worth $5 million) and in 2010 from the Cancer Prevention & Research Institute of Texas (CPRIT) (worth $10.3 million).
The company CEO Dr. Paul Lammers, MD, MSc has provided us more information about Mirna Therapeutics in this recent e-interview with Lead411: